Benjamin Palleiko

Ben is a Senior Advisor on the Frazier Life Sciences team.

Ben joined the Frazier Life Sciences team in 2026 with more than 25 years of experience as an executive in the life sciences industry.

Ben most recently served as Chief Executive Officer and a director of KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a multinational pharmaceutical company he joined in 2016 and led through its $1.9 billion acquisition by Chiesi Group in June 2026. During his tenure, KalVista discovered and developed EKTERLY®, the first and only oral therapy for the treatment of acute hereditary angioedema (HAE) attacks, and executed its successful global commercial launch.

Previously, Ben served as Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings (Nasdaq: ORXE) and Penwest Pharmaceuticals Co. (Nasdaq: PPCO), and spent a decade as an investment banker at firms including Robertson Stephens. Before his business career, Ben served as a Naval Aviator in the U.S. Navy.

Ben holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and an M.A. in International Relations from the University of Chicago.